Brief: Caplin Point Laboratories Receives EIR From FDA For Gummidipoondi Facility
06/01/2025 13:35
Jan 6 (Reuters) - Caplin Point Laboratories Ltd
CAPL.NS :
* CAPLIN POINT LABORATORIES - RECEIVES EIR FROM FDA FOR
GUMMIDIPOONDI FACILITY
* CAPLIN POINT LABORATORIES - USFDA INSPECTION CONCLUDED
WITH ZERO
483 OBSERVATIONS
Source text: ID:nNSE5NFcYs
Further company coverage: CAPL.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Caplin Point Laboratories
See all newsBrief: Caplin Point Laboratories Says US FDA Completes Unannounced Inspection Of Caplin Steriles Gummidipoondi Facility
Brief: Caplin Point Laboratories March-Quarter Consol Net Profit 1.7 Bln Rupees
Brief: Caplin Point Laboratories Unit Receives Final USFDA Approval For ANDA Potassium Phosphates Injection
Brief: Caplin Point Laboratories Says Unit Receives USFDA Approval For Sodium Phosphates Injection
Brief: Caplin Point Laboratories Dec-Quarter Consol Net Profit 1.64 Billion Rupees